Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Sichuan Credit Pharmaceutical Co., Ltd.

Clinicaltrial registered23 Oct 2026

Sichuan Credit Pharmaceutical Co., Ltd.

23 Oct 2026: Trial registered · A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
23 Oct 2026
Title
A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
Conditions
Adjunct in the Treatment of Depressive Disorder
Phase
Not applicable
Study Type
Interventional
Status
Recruiting
Countries
India
Country
India
Reference
NCT07893002
Location
India
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Sichuan Credit Pharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from India

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.